Evidence map›Paper›PMID 39015502›Full record

ArticleFrontiers in oncology2024

Baseline assessment of cervical cancer screening and treatment capacity in 25 counties in Kenya, 2022.

Valerian Mwenda, David Murage, Catherine Kilonzo, Joan-Paula Bor, Patricia Njiri, Lance Osiro, Mary Nyangasi, Marc Arbyn, Philippe Tummers, Marleen Temmerman

Abstract read
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Valerian MwendaNational Cancer Control Program, Ministry of Health, Nairobi, Kenya.
David MurageNational Cancer Control Program, Ministry of Health, Nairobi, Kenya.
Catherine KilonzoField Epidemiology and Laboratory Program, Ministry of Health, Nairobi, Kenya.
Joan-Paula BorNational Cancer Control Program, Ministry of Health, Nairobi, Kenya.
Patricia NjiriNoncommunicable Disease Program, Clinton Health Access Initiative, Nairobi, Kenya.
Lance OsiroNoncommunicable Disease Program, Clinton Health Access Initiative, Nairobi, Kenya.
Mary NyangasiNational Cancer Control Program, Ministry of Health, Nairobi, Kenya.
Marc ArbynUnit of Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Brussels, Belgium.
Philippe TummersDepartment of Human Structure and Repair, Ghent University Hospital, Ghent, Belgium.
Marleen TemmermanDepartment of Obstetrics and Gynaecology, Ghent University Hospital, Ghent, Belgium.

Funding

Global Infectious Diseases and HPV Research Training in KenyaD43TW010905 · FIC · AGA KHAN UNIVERSITY (KENYA) · PI CHUNG, MICHAEL HOONBAE, TEMMERMAN, MARLEEN · 2018 to 2023
$1.2M
FIC NIH HHS D43 TW010905
6 · The paper itself

Abstract

Background: Cervical cancer is the leading cause of cancer deaths among women in Kenya. In the context of the Global strategy to accelerate the elimination of cervical cancer as a public health problem, Kenya is currently implementing screening and treatment scale-up. For effectively tracking the scale-up, a baseline assessment of cervical cancer screening and treatment service availability and readiness was conducted in 25 priority counties. We describe the findings of this assessment in the context of elimination efforts in Kenya. Methods: The survey was conducted from February 2021 to January 2022. All public hospitals in the target counties were included. We utilized healthcare workers trained in preparation for the scale-up as data collectors in each sub-county. Two electronic survey questionnaires (screening and treatment; and laboratory components) were used for data collection. All the health system building blocks were assessed. We used descriptive statistics to summarize the main service readiness indicators. Results: Of 3,150 hospitals surveyed, 47.6% (1,499) offered cervical cancer screening only, while 5.3% (166) offered both screening and treatment for precancer lesions. Visual inspection with acetic acid (VIA) was used in 96.0% (1,599/1,665) of the hospitals as primary screening modality and HPV testing was available in 31 (1.0%) hospitals. Among the 166 hospitals offering treatment for precancerous lesions, 79.5% (132/166) used cryotherapy, 18.7% (31/166) performed thermal ablation and 25.3% (42/166) performed large loop excision of the transformation zone (LLETZ). Pathology services were offered in only 7.1% (17/238) of the hospitals expected to have the service (level 4 and above). Only 10.8% (2,955/27,363) of healthcare workers were trained in cervical cancer screening and treatment; of these, 71.0% (2,097/2,955) were offering the services. Less than half of the hospitals had cervical cancer screening and treatment commodities at time of survey. The main health system strength was presence of multiple screening points at hospitals, but frequent commodity stock-outs was a key weakness. Conclusion: Training, commodities, and diagnostic services are major gaps in the cervical cancer program in Kenya. To meet the 2030 elimination targets, the national and county governments should ensure adequate financing, training, and service integration, especially at primary care level.

Indexed as

baseline assessmentcervical cancerKenyascreeningservice readiness

Identifiers

PMID39015502
PMCPMC11249718

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.